We are live on ! Find out more
SC

Stempoint Capital Portfolio holdings

AUM $522M
1-Year Est. Return 281.95%
This Fund
S&P 500
This Quarter Est. Return
+8.95%
1 Year Est. Return
+281.95%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$312M
AUM Growth
-$2.13M
Cap. Flow
-$1.57M
Cap. Flow %
-0.5%
Top 10 Hldgs %
50%
Holding
82
New
21
Increased
16
Reduced
15
Closed
29

Top Buys

Rank Stock Value
1
MLYS icon
Mineralys Therapeutics
MLYS
+$9.15M
2
LEGN icon
Legend Biotech
LEGN
+$8.75M
3
RYTM icon
Rhythm Pharmaceuticals
RYTM
+$8.75M
4
SNDX icon
Syndax Pharmaceuticals
SNDX
+$8.52M
5
CNTA
Centessa Pharmaceuticals
CNTA
+$8.52M

Top Sells

Rank Stock Value
1
ROIV icon
Roivant Sciences
ROIV
+$21.4M
2
RVMD icon
Revolution Medicines
RVMD
+$11.3M
3
NUVL
Nuvalent
NUVL
+$9.55M
4
XENE icon
Xenon Pharmaceuticals
XENE
+$9.21M
5
CGON icon
CG Oncology
CGON
+$7.1M

Sector Composition

Rank Sector Weight
1 Healthcare 99.17%
2 Financials 0.51%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
APGE icon
26
Apogee Therapeutics
APGE
$10.1B
$3.67M 1.18%
+84,466
New +$3.21M
IDYA icon
27
IDEAYA Biosciences
IDYA
$3.46B
$3.49M 1.12%
165,885
+98,886
+148% +$1.9M
TARA icon
28
Protara Therapeutics
TARA
$229M
$3.47M 1.11%
1,143,677
-46,902
-4% -$162K
BBOT
29
BridgeBio Oncology
BBOT
$666M
$3.29M 1.06%
315,812
+114,912
+57% +$1.24M
EYPT icon
30
EyePoint Inc
EYPT
$1.09B
$3.1M 0.99%
+329,254
New +$2.27M
ARQT icon
31
Arcutis Biotherapeutics
ARQT
$3.47B
$2.88M 0.93%
205,672
-234,401
-53% -$3.29M
RZLT icon
32
Rezolute
RZLT
$421M
$2.88M 0.92%
+644,654
New +$2.39M
TSHA icon
33
Taysha Gene Therapies
TSHA
$1.72B
$2.78M 0.89%
+1,203,941
New +$2.62M
NAMS icon
34
NewAmsterdam Pharma
NAMS
$3.63B
$2.76M 0.89%
152,652
+48,067
+46% +$877K
BHVN icon
35
Biohaven
BHVN
$2.13B
$2.47M 0.79%
174,754
-75,810
-30% -$1.35M
REGN icon
36
Regeneron Pharmaceuticals
REGN
$71.2B
$2.45M 0.79%
+4,672
New +$2.61M
BBIO icon
37
BridgeBio Pharma
BBIO
$15.7B
$2.36M 0.76%
54,630
-153,807
-74% -$5.59M
JANX icon
38
Janux Therapeutics
JANX
$966M
$2.08M 0.67%
89,933
-252,129
-74% -$6.64M
ORIC icon
39
Oric Pharmaceuticals
ORIC
$1.11B
$2.04M 0.65%
+200,785
New +$1.35M
MBX
40
MBX Biosciences
MBX
$2.78B
$1.61M 0.52%
141,021
+44,406
+46% +$452K
PCSC
41
Perceptive Capital Solutions
PCSC
$124M
$1.59M 0.51%
150,000
– –
PRAX icon
42
Praxis Precision Medicines
PRAX
$8.59B
$1.36M 0.44%
+32,255
New +$1.23M
GHRS icon
43
GH Research
GHRS
$2B
$1.23M 0.39%
+100,826
New +$1.11M
TNGX icon
44
Tango Therapeutics
TNGX
$4.5B
$1.07M 0.34%
+208,800
New +$516K
PTGX icon
45
Protagonist Therapeutics
PTGX
$8.49B
$927K 0.3%
16,770
-32,471
-66% -$1.56M
TECX
46
Tectonic Therapeutic
TECX
$578M
$795K 0.26%
+40,000
New +$811K
ADCT icon
47
ADC Therapeutics
ADCT
$172M
$759K 0.24%
+283,286
New +$596K
VRNA
48
DELISTED
Verona Pharma
VRNA
$701K 0.22%
+7,407
New +$548K
ABVX
49
Abivax
ABVX
$12B
$671K 0.22%
+87,748
New +$572K
ROIV icon
50
CALL
Roivant Sciences
ROIV
$24.4B
$618K 0.2%
+915,000
New +$9.92M
1
2
3 4

Similar funds

JE
JMAC Enterprises Newtown, Pennsylvania $522M AUM 15.34% 1-Year Est. Return
GS
GWN Securities Palm Beach Gardens, Florida $523M AUM 20.1% 1-Year Est. Return
LT
Legacy Trust Grand Rapids, Michigan $522M AUM 23.56% 1-Year Est. Return
WFA
WestHill Financial Advisors San Rafael, California $523M AUM 15.95% 1-Year Est. Return
TCM
TruNorth Capital Management Kalamazoo, Michigan $522M AUM 14.26% 1-Year Est. Return
SCM
Shah Capital Management Raleigh, North Carolina $521M AUM 46.95% 1-Year Est. Return
ETS
ESL Trust Services Rochester, New York $524M AUM 17.18% 1-Year Est. Return
CM
Conifer Management New York $524M AUM 14.11% 1-Year Est. Return

Stempoint Capital's Q2 2025 Portfolio in Review

As of Q2 2025, Stempoint Capital held 82 positions worth $312M, down 0.68% from $314M the previous quarter. Its ten largest holdings account for 50% of the portfolio.

Stempoint Capital's Q2 2025 filing shows 21 new, 16 increased, 15 reduced and 29 closed positions. Its largest new stake was Mineralys Therapeutics: 631,586 shares worth $8.55M. The largest sale was Roivant Sciences, an estimated $21.4M.

By sector, the portfolio is most concentrated in Healthcare at 99% of assets, down from 99% a quarter earlier, followed by Financials.

  • Stempoint Capital's largest Q2 2025 buy was Mineralys Therapeutics: 631,586 shares worth $8.55M.
  • Stempoint Capital added most to Rhythm Pharmaceuticals in Q2 2025, an estimated $8.75M increase.
  • Stempoint Capital's biggest Q2 2025 reduction was Roivant Sciences, cutting an estimated $21.4M.
  • Stempoint Capital fully exited Revolution Medicines in Q2 2025, selling an estimated $11.3M.
  • Stempoint Capital's ten largest holdings make up 50% of its $312M portfolio in Q2 2025.
  • Stempoint Capital opened 21 new positions and closed 29 in Q2 2025.
  • Stempoint Capital's portfolio value fell 0.68% quarter-over-quarter to $312M.

Based on Stempoint Capital's 13F filing for Q2 2025, filed 14 Aug 2025.